Filter by: patients
Home > Community Treatment Reports and Side Effects > MS Phase 3 Study Laquinimod Treatment Report
What is MS Phase 3 Study Laquinimod?

NCT00509145 is a completed randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis. Other study names are MS-LAQ-301, EUDRACT 2007-003226-19.

0 patients have reported taking MS Phase 3 Study Laquinimod .

Report created on May 23, 2012.